Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
ITiTeos Therapeutics, Inc. logo

iTeos Therapeutics, Inc. (ITOS)

NASDAQ Global Market · Currency in USD
$10.15 ▲ +0.02 (+0.20%)
At close: Aug 29, 4:00 PM ET. Market closed.

Summary

Previous Close
$10.13
Open
$10.15
Day's Range
$10.15 – $10.15
52 Week Range
$4.80 – $17.63
Volume
11,006,826
Avg. Volume
1,341,915
Market Cap
$448.68M
Beta (5Y Monthly)
1.49
PE Ratio (TTM)
--
EPS (TTM)
-$3.32
Earnings Date
--
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$18.20

Profile: iTeos Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
173
CEO
Michel Detheux

iTeos Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the discovery and advancement of immuno-oncology therapies for patients. The company's pipeline includes two principal investigational drugs: inupadenant, a small molecule designed as an antagonist of adenosine A2AR, which is currently undergoing Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT (T-cell immunoreceptor with Ig and ITIM domains), presently in Phase 1/2 clinical assessment. Furthermore, EOS-448's mechanism involves engaging the Fc gamma receptor (FcγR) to activate dendritic cells and macrophages, thereby promoting antibody-dependent cellular cytotoxicity (ADCC).

Earnings

DateEst.Actual
Aug 6, 2025-$1.12-$1.51Miss
Apr 28, 2025-$0.94-$0.80Beat
Mar 5, 2025-$1.14-$1.01Beat
Nov 12, 2024-$1.18-$1.05Beat
Aug 8, 2024-$1.04-$0.18Beat
May 10, 2024-$1.02-$1.07Miss

Analyst view

Consensus price target
$18.20 ▲ +79.3%
Range $9.00 – $46.00
Rating: Hold
Buy 38% · Hold 63% · Sell 0%

Get free alerts on ITOS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.